• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

作为生物还原药物的DNA结合剂的脂肪族胺N-氧化物

Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs.

作者信息

Patterson L H, Craven M R, Fisher G R, Teesdale-Spittle P

机构信息

Department of Pharmacy, School of Applied Sciences, De Montfort University, Leicester, UK.

出版信息

Oncol Res. 1994;6(10-11):533-8.

PMID:7620222
Abstract

The DNA binding and cytotoxicity of four intercalating agents, namely bis-alkylamino (-N(CH2)2N(CH3)2) substituted anthraquinone, anthrapyrazole and anthracene, and mono (N(CH2)2N(CH3)2) acridinone, have been compared with their respective aliphatic amine N-oxides -N(CH2)2N+(O-)(CH3)2. The results show that, unlike the intercalators, the N-oxides do not bind to DNA. Molecular modelling illustrates that the delta + nature of the intercalator alkylamino side chains in the protonated form allows for an attractive electrostatic interaction with phosphates of the DNA backbone, whereas the delta- partial charge on the N-oxide makes such an interaction not permissible; indeed, the electrostatic interaction with the DNA phosphates will be repulsive. The N-oxides show little or no cytotoxicity against V79 cells at concentrations equimolar to the IC90 (concentration that inhibits 90% of cell proliferation) of the respective intercalators. However, the cytotoxicity of anthrapyrazole N-oxide against hypoxic V79 cells in the presence of an activating system of S9 liver fraction was enhanced significantly. The results indicate that N-oxides of DNA-affinic agents have potential as bioreductive prodrugs, since they possess low aerobic toxicity but under hypoxic conditions can be metabolised to a potent cytotoxic species presumed to be a DNA-binding tertiary amine.

摘要

已将四种嵌入剂,即双烷基氨基(-N(CH2)2N(CH3)2)取代的蒽醌、蒽吡唑和蒽,以及单(N(CH2)2N(CH3)2)吖啶酮的DNA结合和细胞毒性与其各自的脂肪族胺N-氧化物-N(CH2)2N+(O-)(CH3)2进行了比较。结果表明,与嵌入剂不同,N-氧化物不与DNA结合。分子模拟表明,质子化形式的嵌入剂烷基氨基侧链的δ+性质允许与DNA主链的磷酸盐形成有吸引力的静电相互作用,而N-氧化物上的δ-部分电荷使得这种相互作用不被允许;实际上,与DNA磷酸盐的静电相互作用将是排斥性的。在与各自嵌入剂的IC90(抑制90%细胞增殖的浓度)等摩尔的浓度下,N-氧化物对V79细胞几乎没有或没有细胞毒性。然而,在存在S9肝匀浆激活系统的情况下,蒽吡唑N-氧化物对缺氧V79细胞的细胞毒性显著增强。结果表明,DNA亲和剂的N-氧化物有作为生物还原前药的潜力,因为它们具有低需氧毒性,但在缺氧条件下可代谢为一种假定为与DNA结合的叔胺的强效细胞毒性物质。

相似文献

1
Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs.作为生物还原药物的DNA结合剂的脂肪族胺N-氧化物
Oncol Res. 1994;6(10-11):533-8.
2
Nitracrine N-oxides: effects of variations in the nature of the side chain N-oxide on hypoxia-selective cytotoxicity.硝吖啶N-氧化物:侧链N-氧化物性质变化对缺氧选择性细胞毒性的影响。
Anticancer Drug Des. 1999 Dec;14(6):487-97.
3
Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N.叔胺氮氧化物作为生物还原药物:DACA氮氧化物、硝吖啶氮氧化物和AQ4N。
Br J Cancer Suppl. 1996 Jul;27:S43-7.
4
Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs. Cytotoxicity, DNA binding, cellular uptake, and metabolism.吖啶DNA嵌入剂的芳香胺和叔胺N-氧化物作为生物还原药物的比较。细胞毒性、DNA结合、细胞摄取和代谢。
Biochem Pharmacol. 2000 Oct 1;60(7):969-78. doi: 10.1016/s0006-2952(00)00420-2.
5
Synthesis and anti-cancer activity of 2,6-disubstituted N-methylpiperidine derivatives and their N-oxides.2,6-二取代N-甲基哌啶衍生物及其N-氧化物的合成与抗癌活性
Anticancer Drug Des. 1996 Sep;11(6):421-38.
6
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.作为嵌入型细胞毒性剂的1-[(ω-氨基烷基)氨基]-4-[N-(ω-氨基烷基)氨基甲酰基]-9-氧代-9,10-二氢吖啶:合成、DNA结合及生物学评价
J Med Chem. 1997 Nov 7;40(23):3749-55. doi: 10.1021/jm970114u.
7
Cytotoxic palladium complexes of bioreductive quinoxaline N1,N4-dioxide prodrugs.生物还原喹喔啉 N1,N4-二氧化物前药的细胞毒性钯配合物
Bioorg Med Chem. 2009 Feb 15;17(4):1623-9. doi: 10.1016/j.bmc.2008.12.064. Epub 2009 Jan 3.
8
Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.吲哚咔唑类抗肿瘤药物NB-506的F环N-酰亚胺处的取代作用增强了细胞毒性、DNA结合能力以及拓扑异构酶I抑制活性。
J Med Chem. 1999 Jul 29;42(15):2927-35. doi: 10.1021/jm990108t.
9
9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): a novel DNA-affinic bioreductive agent as chemosensitizer. I.
Oncol Res. 1997;9(5):249-57.
10
The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.功能基团对DT-黄递酶还原和激活醌类生物还原剂的影响。
Cancer Chemother Pharmacol. 2002 Feb;49(2):101-10. doi: 10.1007/s00280-001-0395-1. Epub 2001 Nov 24.

引用本文的文献

1
Targeting DNA topoisomerase IIα (TOP2A) in the hypoxic tumour microenvironment using unidirectional hypoxia-activated prodrugs (uHAPs).针对缺氧肿瘤微环境中的 DNA 拓扑异构酶 IIα(TOP2A)使用单向缺氧激活前药(uHAPs)。
IUBMB Life. 2023 Jan;75(1):40-54. doi: 10.1002/iub.2619. Epub 2022 May 2.
2
Hypoxia-targeted drug delivery.缺氧靶向药物递送。
Chem Soc Rev. 2019 Feb 4;48(3):771-813. doi: 10.1039/c8cs00304a.
3
Biological evaluation of the toxicity and the cell cycle interruption by some benzimidazole derivatives.某些苯并咪唑衍生物的毒性及细胞周期阻断的生物学评价
Tumour Biol. 2016 Aug;37(8):11135-45. doi: 10.1007/s13277-016-4828-1. Epub 2016 Mar 1.
4
ABC transporters in CSCs membranes as a novel target for treating tumor relapse.癌症干细胞膜中的ABC转运蛋白作为治疗肿瘤复发的新靶点。
Front Pharmacol. 2014 Jul 10;5:163. doi: 10.3389/fphar.2014.00163. eCollection 2014.
5
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.生物还原前药作为癌症治疗药物:靶向肿瘤缺氧
Chin J Cancer. 2014 Feb;33(2):80-6. doi: 10.5732/cjc.012.10285. Epub 2013 Jul 12.
6
Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1.CYP2S1 和 CYP2W1 高效激活抗癌剂 AQ4N 的缺氧作用。
Mol Pharmacol. 2010 Sep;78(3):497-502. doi: 10.1124/mol.110.065045. Epub 2010 Jun 21.
7
Reductive heme-dependent activation of the n-oxide prodrug AQ4N by nitric oxide synthase.一氧化氮合酶对氮氧化物前药AQ4N的还原性血红素依赖性激活作用。
J Med Chem. 2008 Aug 28;51(16):5118-20. doi: 10.1021/jm800496s. Epub 2008 Aug 6.
8
Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent.生物还原激活的抗肿瘤药物AQ4N增强小鼠肿瘤的化疗和放疗效果
Br J Cancer. 2000 Jun;82(12):1984-90. doi: 10.1054/bjoc.2000.1163.
9
Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N.叔胺氮氧化物作为生物还原药物:DACA氮氧化物、硝吖啶氮氧化物和AQ4N。
Br J Cancer Suppl. 1996 Jul;27:S43-7.
10
Recent developments in the design of bioreductive drugs.生物还原药物设计的最新进展。
Br J Cancer Suppl. 1996 Jul;27:S32-8.